FOREST SYNAPTON ALZHEIMER's NDA FILING POSSIBLE FOR 1995
Executive Summary
FOREST SYNAPTON ALZHEIMER's NDA FILING POSSIBLE FOR 1995 the company projects in its 1994 annual report. "We have completed one study which demonstrates safety and efficacy and we are presently well into two additional studies," Forest said. "We expect to file an NDA next year." The company had projected an NDA filing for physostigmine as early as 1991 based on its first pivotal study. However, FDA subsequently indicated that it would require longer trials for approval of Alzheimer's agents.